

Recessive *LAMC3* mutations cause malformations of occipital cortical development

Tanyeri Barak^{1-3,18}, Kenneth Y Kwan^{2,4,18}, Angeliki Louvi^{1,2}, Veysi Demirbilek⁵, Serap Saygi⁶, Beyhan Tüysüz⁷, Murim Choi³, Hüseyin Boyacı^{8,9}, Katja Doerschner^{8,9}, Ying Zhu^{2,4}, Hande Kaymakçalan¹⁰, Saliha Yılmaz¹⁻³, Mehmet Bakırcioğlu¹⁻³, Ahmet Okay Çağlayan¹⁻³, Ali Kemal Öztürk¹⁻³, Katsuhito Yasuno¹⁻³, William J Brunken^{11,12}, Ergin Atalar⁹, Cengiz Yalçınkaya⁵, Alp Dinçer¹³, Richard A Bronen^{1,14}, Shrikant Mane^{3,15}, Tayfun Özçelik¹⁶, Richard P Lifton^{3,17}, Nenad Šestan^{2,4}, Kaya Bilgüvar¹⁻³ & Murat Günel¹⁻³

The biological basis for regional and inter-species differences in cerebral cortical morphology is poorly understood. We focused on consanguineous Turkish families with a single affected member with complex bilateral occipital cortical gyration abnormalities. By using whole-exome sequencing, we initially identified a homozygous 2-bp deletion in *LAMC3*, the laminin $\gamma 3$ gene, leading to an immediate premature termination codon. In two other affected individuals with nearly identical phenotypes, we identified a homozygous nonsense mutation and a compound heterozygous mutation. In human but not mouse fetal brain, *LAMC3* is enriched in postmitotic cortical plate neurons, localizing primarily to the somatodendritic compartment. *LAMC3* expression peaks between late gestation and late infancy, paralleling the expression of molecules that are important in dendritogenesis and synapse formation. The discovery of the molecular basis of this unusual occipital malformation furthers our understanding of the complex biology underlying the formation of cortical gyrations.

Extensive and stereotypic gyrations (convolutions) of the cerebral cortex are striking features of the human brain^{1,2}. The cerebral cortex develops through a series of highly coordinated phases including proliferation of neural progenitors, migration of postmitotic cells from the germinal matrix to the newly forming cortex and organization of the mature cortical cytoarchitecture. Among these processes, the biological basis for the formation of cortical convolutions has been the subject of much debate³⁻⁷. The study of malformations of


cortical development (MCD) that interfere with the proper formation of the typical cortical gyration pattern in humans provides a unique opportunity to understand this elegant process. We applied whole-exome capture and sequencing to the study of consanguineous, single-affected-member Turkish kindreds with malformations of occipital cortex gyration, notably characterized by the presence of both pachygyria and polymicrogyria^{8,9}, entities traditionally thought to arise from different pathogenic mechanisms reflecting abnormalities in neuronal migration and cortical organization, respectively¹⁰.

The first index case, designated NG 49-1 (Fig. 1a, Supplementary Fig. 1 and Supplementary Note), presented to medical attention with absence seizures and mild developmental delay during early childhood. Magnetic resonance imaging (MRI) revealed bilateral occipital pachygyria mainly localizing to the lateral surface, characterized by smoothening of the occipital cortices with loss of secondary and tertiary gyri, and polymicrogyric areas, characterized by the formation of numerous small gyri at the junction of the parieto-occipital lobes (Fig. 1b-f and Supplementary Videos 1 and 2). Following genome-wide genotyping, which confirmed consanguinity with an inbreeding coefficient of 5.77, and determination of homozygous genomic segments (>2.5 cM each) (Supplementary Table 1), we performed whole-exome capture and sequencing with high sensitivity and specificity using NimbleGen liquid-phase arrays and the Illumina Genome Analyzer-IIx instrument as described previously¹¹ (Supplementary Tables 2 and 3). By focusing on the homozygous intervals (Supplementary Table 4), we identified a homozygous 2-bp deletion in *LAMC3* (*Laminin $\gamma 3$*), which is located on chromosome 9; this mutation is inferred to result

¹Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA. ²Department of Neurobiology, Yale School of Medicine, New Haven, Connecticut, USA. ³Department of Genetics, Center for Human Genetics and Genomics and Program on Neurogenetics, Yale School of Medicine, New Haven, Connecticut, USA. ⁴Kavli Institute for Neuroscience, Yale School of Medicine, New Haven, Connecticut, USA. ⁵Division of Child Neurology, Department of Neurology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey. ⁶Department of Neurology, Hacettepe University School of Medicine, Ankara, Turkey. ⁷Division of Genetics, Department of Pediatrics, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey. ⁸Department of Psychology, Bilkent University, Ankara, Turkey. ⁹National Magnetic Resonance Research Center, Bilkent University, Ankara, Turkey. ¹⁰Faculty of Arts and Sciences, Bahcesehir University, Istanbul, Turkey. ¹¹Department of Cell Biology, State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York, USA. ¹²Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn, New York, USA. ¹³Department of Radiology, Acibadem University School of Medicine, Istanbul, Turkey. ¹⁴Department of Radiology, Yale School of Medicine, New Haven, Connecticut, USA. ¹⁵Yale Center for Genome Analysis, Yale School of Medicine, New Haven, Connecticut, USA. ¹⁶Department of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Ankara, Turkey. ¹⁷Howard Hughes Medical Institute, Yale School of Medicine, New Haven, Connecticut, USA. ¹⁸These authors contributed equally to this work. Correspondence should be addressed to M.G. (murat.gunel@yale.edu).

Received 24 January; accepted 21 April; published online 15 May 2011; doi:10.1038/ng.836

Figure 3 Species differences in expression of *LAMC3* in the cerebral cortex. (a) *In situ* hybridization of mid-fetal human brain (20 PCW) shows robust *LAMC3* expression in the cortical plate (CP) and within the germinal zones of the neocortical wall, including the ventricular zone (VZ) and subventricular zone (SVZ), and the outer SVZ (oSVZ). IZ, intermediate zone. (b) In contrast, *Lamc3* expression in the developing mouse brain (E13.5 to E17.5) is limited to the vasculature and meninges. (c) Human fetal neocortex (20 PCW) immunostained for *LAMC3* (green), the post-mitotic neuronal marker NeuN (red) and the neural stem cell marker SOX2 (blue) shows *LAMC3* to be strongly expressed in post-mitotic NeuN-positive neurons that have migrated and settled in the cortical plate (CP). Although *LAMC3* is not expressed in the intermediate zone, which contains migrating neurons, expression is seen in SOX2-positive neural stem cells in the ventricular zone and subventricular zone. In addition, *LAMC3* is expressed in the basal lamina of blood vessels. Composite images are shown on the right. See **Supplementary Figure 5** for individual panels.



staring and blinking spells (**Supplementary Note** and **Supplementary Video 3**). On her current examination at age 33 years, this subject was found to be neurologically intact with normal visual acuity and reportedly average intelligence. MRI revealed prominent bilateral smoothing and thickening of the lateral occipital cortex, which is associated with polymicrogyria (**Fig. 2b,c**, **Supplementary Fig. 3a** and **Supplementary Videos 4** and **5**). However, despite these gross structural findings, retinotopic mapping using functional MRI indicated that the relative locations and functions of the primary visual areas were largely indistinguishable from control subjects (**Fig. 2d**, **Supplementary Note** and **Supplementary Fig. 3b**)^{12,13}. Nonetheless, diffusion tensor imaging (DTI) tractography showed markedly lower fractional anisotropy and elevated radial diffusivity values in areas adjacent to the pachygyric region, suggesting microstructural changes of white matter, possibly caused by fiber disorganization (**Fig. 2e** and **Supplementary Note**).

Finally, we investigated the remaining affected individuals in our neurogenetics cohort of over 600 people to assess whether any had similar MRI findings. We identified only one other individual, NG 50-1, who had an almost identical MRI picture. This subject was the product of a second cousin marriage (**Fig. 2f**) and presented to medical attention at the age of 11 with episodes of vision loss consistent with seizures; imaging studies again revealed bilateral occipital pachygyria associated with polymicrogyria (**Fig. 2g**, **Supplementary Fig. 1b** and **Supplementary Note**). We found NG 50-1 to be heterozygous for the interval surrounding *LAMC3*, suggesting potential genetic locus heterogeneity (**Supplementary Table 5**). However, exome sequencing revealed no homozygous nonsense or frameshift mutations, whereas all eight new homozygous missense variants identified affected non-conserved domains of various proteins located within the autozygous intervals, suggesting that they were unlikely to be disease causing (**Supplementary Table 6**). Subsequent examination of the *LAMC3* sequence available from the exome sequencing data followed by confirmation using PCR and Sanger sequencing identified a compound heterozygous mutation, with a premature termination mutation at codon 386 (resulting in p.Gln386X) and a missense mutation (resulting in p.Gly350Arg) at a position completely conserved among vertebrate orthologs (**Supplementary Fig. 2c** and **Supplementary Fig. 4**) and predicted to be damaging. One mutation was inherited from each parent (**Supplementary Fig. 2c**).

None of the four mutations newly discovered in *LAMC3* had been previously reported in the dbSNP or 1000 Genomes databases and all were absent from our screening of 400 Turkish control subjects. They were also absent from our whole-exome sequence database


of 1,023 subjects with non-neurological diseases in which we only identified four different heterozygous *LAMC3* variants (p.Cys273Tyr, p.Gly275Glu, p.Gln928X and c.976+1G>A) with a collective allele frequency of less than 1 in 500, consistent with these deleterious alleles being under strong purifying selection. The rarity of such deleterious mutations and the finding of new homozygous and compound heterozygous mutations in *LAMC3* in all three subjects with occipital pachygyria and polymicrogyria provide conclusive evidence that recessive *LAMC3* mutations cause this syndrome.

We next investigated the expression of *LAMC3* in the developing human fetal brain at 20 post-conceptual weeks (PCW) and showed that it was enriched in the cortical plate, a dense layer of post-migratory pyramidal neurons, and was also present at lower levels in the ventricular and subventricular zones, the germinal layers of the cortex (**Fig. 3** and **Supplementary Fig. 5**). In contrast, we observed a strikingly different expression pattern in the embryonic mouse brain, where *Lamc3* expression was absent from the neuronal cells and was instead restricted to the embryonic cerebral vasculature and the meninges from embryonic day (E) 13.5 onwards (**Fig. 3b** and **Supplementary Fig. 6**). This finding, which is consistent with the previous observation that *Lamc3* deletion in mice is silent with no apparent phenotype¹⁴, suggested that *LAMC3* expression has diverged on the mammalian lineage, making the mouse a poor model for understanding *LAMC3* function in human cortical development.

We then investigated the spatial and temporal changes in expression during human cortical development and first detected *LAMC3* transcripts after mid-gestation, which peaked at an interval extending from late fetal development to late infancy (12 months) (**Fig. 4a**), coinciding with the period of cortical organization that takes place after neural stem cell proliferation and migration of postmitotic neurons to the cortical plate. Examination of *LAMC3* expression at the subcellular level supported these observations, showing that *LAMC3* primarily localizes to the soma and apical dendrite of pyramidal neurons (**Fig. 4b,c** and **Supplementary Fig. 7**) and is barely detected along or near the axons (**Fig. 4d**). A role for *LAMC3* in extracellular matrix organization of the somatodendritic compartment was further supported by an analysis of the Human Brain Transcriptome database¹⁵, showing that the developmental expression pattern of *LAMC3* parallels that of other molecules important for dendritogenesis (**Fig. 4e**)^{16,17} and synapse formation (**Supplementary Note**, **Supplementary Fig. 8** and **Supplementary Table 7**)¹⁸.

Laminins are extracellular cell adhesion molecules mostly localizing to basement membranes¹⁹ and are essential for early embryonic development. They are cross-shaped heterotrimers consisting of α , β

Figure 4 Temporal and spatial *LAMC3* expression pattern. (a) Heat map of *LAMC3* expression in human brain. The strongest expression was seen between late gestation (24–38 PCW) and late infancy (6–12 post-natal months) and is more prominent within the temporo-occipital lobes as compared to frontal regions. PCW, post-conceptual weeks; m, month; y, year. #Brain regions sampled are listed under Methods. (b) Human fetal neocortex (20 PCW) immunostained for *LAMC3* (green) and the neuronal marker SMI-312 (red) reveals high expression in pyramidal neurons in a punctate pattern primarily localizing to the somata and apical dendrites (arrowheads), both at the proximal and distal segments. *LAMC3* expression is not detected on axons as they leave the cortical plate (CP) and enter the subplate (SP). (c) In cortical layer 2, *LAMC3* (green) is localized to bundles of distal apical dendrites (arrowhead) immuno-positive for MAP2 (red), a marker for dendrites. (d) In the cortical plate, *LAMC3* (green) is expressed in pyramidal neurons. In the white matter (WM), where bundles of SRGAP1-positive corticofugal axons (red) are abundantly present, *LAMC3* is weak or absent on axons but highly expressed in the neighboring blood vessels. (e) *LAMC3* expression (black line) parallels that of genes known to be expressed during the period of dendritogenesis (blue line) within the V1 visual cortex (V1C) during late fetal and early post-natal periods and declines after infancy. For a and e, log₂-transformed expression values are shown (Online Methods).



and γ chains. Mutations in various laminin molecules lead to diverse pathologies including Pierson syndrome (congenital nephrotic syndrome with or without ocular abnormalities caused by *LAMB2* mutations), junctional epidermolysis bullosa ($\alpha 3$, $\beta 3$ and $\gamma 2$ chain mutations) and congenital merosin-deficient muscular dystrophy type 1A (*LAMA2* mutations), which is sometimes associated with cobblestone lissencephaly and occipital pachygyria^{19–21}. Mutations in *LAMC3* have not previously been reported. *LAMC3* is not thought to associate exclusively with the basement membrane—it can bind either to nidogen or to $\alpha 6\beta 1$ -integrin and is expressed in mouse retina and brain vessels^{22–25}, with *Lamc3* knockout mice lacking any overt phenotypes^{14,26}.

Little is known about the precise molecular mechanisms underlying human cortical gyration. Here we present conclusive genetic evidence that recessive *LAMC3* mutations cause human occipital cortical malformations characterized by complex gyration abnormalities and challenge the concept that cortical smoothing needs to be caused by disruption of early events in cortical neuronal migration exclusively. Further studies are needed to identify other molecules involved in the intricate process of cortical organization and to understand why the phenotype associated with *LAMC3* mutations is restricted to the occipital lobes.

URLs. dbSNP, <http://www.ncbi.nlm.nih.gov/projects/SNP/>; 1000 Genomes Project, <http://www.1000genomes.org/>; Human Brain Transcriptome database, <http://www.humanbraintranscriptome.org/>; RefSeq, <http://www.ncbi.nlm.nih.gov/RefSeq/>; DAVID Bioinformatics Resources, <http://david.abcc.ncifcrf.gov/>; Freesurfer, <http://surfer.nmr.mgh.harvard.edu/>; Java programming package, <http://billkent.edu/tr/~hboyaci/PsychWithJava>; MedINRIA, <http://www-sop.inria.fr/asclepios/software/MedINRIA/index.php>.

METHODS

Methods and any associated references are available in the online version of the paper at <http://www.nature.com/naturegenetics/>.

Accession codes. *LAMC3* data are deposited in RefSeq under accession number NM_006059.

Note: Supplementary information is available on the Nature Genetics website.

ACKNOWLEDGMENTS

We are indebted to the subjects and families who have contributed to this study. We would like to thank M. State and J. Noonan for critical comments regarding the study and C. Camputaro for her help with the imaging studies. We acknowledge the use of Yale University Biomedical High Performance Computing Center for data analysis and storage. This study was supported by the Yale Program on Neurogenetics, the Yale Center for Human Genetics and Genomics, and US National Institutes of Health grants RC2NS070477 (to M.G.), UL1RR024139NIH (Yale Clinical and Translational Science Award) and UO1MH081896 (to N.S.). SNP genotyping was supported in part by a US National Institutes of Health Neuroscience Microarray Consortium award U24 NS051869-02S1 (to S.M.).

AUTHOR CONTRIBUTIONS

M.G. designed the study, and T.B., K.Y.K., A.L., R.P.L., N.S., K.B. and M.G. designed the experiments. T.B., K.Y.K., A.L., K.B., S.Y., M.B., A.O.C., A.K.O. and S.M. performed the experiments. V.D., S.S., B.T., H.K. and C.Y. identified, consented and recruited the study subjects and provided clinical information. A.D. and R.A.B. performed and evaluated magnetic resonance imaging. T.O., H.B., K.D. and E.A. performed and evaluated three-dimensional cortical reconstruction and functional imaging studies. M.C. and R.P.L. developed the bioinformatics scripts for data analysis. W.J.B. provided critical reagents. T.B., T.O., K.Y., K.B., R.P.L. and M.G. analyzed the genetics data. K.Y.K., A.L., Y.Z., N.S. and M.G. analyzed the expression data. T.B., K.Y.K., A.L., R.P.L., N.S., K.B. and M.G. wrote the paper.

COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details accompany the full-text HTML version of the paper at <http://www.nature.com/naturegenetics/>.

Published online at <http://www.nature.com/naturegenetics/>.

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>.

1. Rakic, P. Specification of cerebral cortical areas. *Science* **241**, 170–176 (1988).
2. Hofman, M.A. Size and shape of the cerebral cortex in mammals. I. The cortical surface. *Brain Behav. Evol.* **27**, 28–40 (1985).
3. Caviness, V.S. Jr. Mechanical model of brain convolitional development. *Science* **189**, 18–21 (1975).
4. Van Essen, D.C. A tension-based theory of morphogenesis and compact wiring in the central nervous system. *Nature* **385**, 313–318 (1997).
5. Kriegstein, A., Noctor, S. & Martinez-Cerdeno, V. Patterns of neural stem and progenitor cell division may underlie evolutionary cortical expansion. *Nat. Rev. Neurosci.* **7**, 883–890 (2006).
6. Piao, X. *et al.* G protein-coupled receptor-dependent development of human frontal cortex. *Science* **303**, 2033–2036 (2004).
7. Kostovic, I. & Rakic, P. Developmental history of the transient subplate zone in the visual and somatosensory cortex of the macaque monkey and human brain. *J. Comp. Neurol.* **297**, 441–470 (1990).
8. Ferrie, C.D., Jackson, G.D., Giannakodimos, S. & Panayiotopoulos, C.P. Posterior agyria-pachygyria with polymicrogyria: evidence for an inherited neuronal migration disorder. *Neurology* **45**, 150–153 (1995).
9. Ben Cheikh, B.O. *et al.* A locus for bilateral occipital polymicrogyria maps to chromosome 6q16–q22. *Neurogenetics* **10**, 35–42 (2009).
10. Barkovich, A.J., Kuzniecky, R.I., Jackson, G.D., Guerrini, R. & Dobyns, W.B. A developmental and genetic classification for malformations of cortical development. *Neurology* **65**, 1873–1887 (2005).
11. Bilgüvar, K. *et al.* Whole-exome sequencing identifies recessive *WDR62* mutations in severe brain malformations. *Nature* **467**, 207–210 (2010).
12. Sereno, M.I. *et al.* Borders of multiple visual areas in humans revealed by functional magnetic resonance imaging. *Science* **268**, 889–893 (1995).
13. Wandell, B.A., Dumoulin, S.O. & Brewer, A.A. Visual field maps in human cortex. *Neuron* **56**, 366–383 (2007).
14. Dénes, V. *et al.* Laminin deficits induce alterations in the development of dopaminergic neurons in the mouse retina. *Vis. Neurosci.* **24**, 549–562 (2007).
15. Johnson, M.B. *et al.* Functional and evolutionary insights into human brain development through global transcriptome analysis. *Neuron* **62**, 494–509 (2009).
16. Mrzljak, L., Uylings, H.B., Kostovic, I. & van Eden, C.G. Prenatal development of neurons in the human prefrontal cortex. II. A quantitative Golgi study. *J. Comp. Neurol.* **316**, 485–496 (1992).
17. Petanjek, Z., Judas, M., Kostovic, I. & Uylings, H.B. Lifespan alterations of basal dendritic trees of pyramidal neurons in the human prefrontal cortex: a layer-specific pattern. *Cereb. Cortex* **18**, 915–929 (2008).
18. Huttenlocher, P.R. & Dabholkar, A.S. Regional differences in synaptogenesis in human cerebral cortex. *J. Comp. Neurol.* **387**, 167–178 (1997).
19. Durbeej, M. Laminins. *Cell Tissue Res.* **339**, 259–268 (2010).
20. Helbling-Leclerc, A. *et al.* Mutations in the laminin alpha 2-chain gene (*LAMA2*) cause merosin-deficient congenital muscular dystrophy. *Nat. Genet.* **11**, 216–218 (1995).
21. Jones, K.J. *et al.* The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review. *J. Med. Genet.* **38**, 649–657 (2001).
22. Gersdorff, N., Kohfeldt, E., Sasaki, T., Timpl, R. & Miosge, N. Laminin $\gamma 3$ chain binds to nidogen and is located in murine basement membranes. *J. Biol. Chem.* **280**, 22146–22153 (2005).
23. Koch, M. *et al.* Characterization and expression of the laminin $\gamma 3$ chain: a novel, non-basement membrane-associated, laminin chain. *J. Cell Biol.* **145**, 605–618 (1999).
24. Libby, R.T. *et al.* Laminin expression in adult and developing retinae: evidence of two novel CNS laminins. *J. Neurosci.* **20**, 6517–6528 (2000).
25. Yan, H.H. & Cheng, C.Y. Laminin $\alpha 3$ forms a complex with $\beta 3$ and $\gamma 3$ chains that serves as the ligand for $\alpha 6\beta 1$ -integrin at the apical ectoplasmic specialization in adult rat testes. *J. Biol. Chem.* **281**, 17286–17303 (2006).
26. Pinzón-Duarte, G., Daly, G., Li, Y.N., Koch, M. & Brunken, W.J. Defective formation of the inner limiting membrane in laminin $\alpha 2$ - and $\gamma 3$ -null mice produces retinal dysplasia. *Invest. Ophthalmol. Vis. Sci.* **51**, 1773–1782 (2010).

ONLINE METHODS

Human subjects. The study protocol was approved by the Yale Human Investigation Committee (HIC) (protocol number 0908005592). Institutional review board approvals for genetic and MRI studies, along with written consent from all study subjects, were obtained by the referring physicians at the participating institutions. All fetal human tissues were collected under guidelines approved by the Yale HIC (protocol number 0605001466). Human fetal brains at 20 and 22 weeks of gestation were obtained from the Human Fetal Tissue Repository at the Albert Einstein College of Medicine (CCI number 1993-042).

Genome-wide genotyping. The Illumina Platform was used for genome-wide genotyping and analysis of the samples. Human 610K Quad BeadChips were used according to the manufacturer's protocol (Illumina).

Exome capture and sequencing. NimbleGen 2.1M human exome array version 1.0 (Roche Nimblegen, Inc.) was used to capture the exomes of samples NG 49-1 and NG 50-1 according to the manufacturer's protocol, with modifications^{11,27}. Sequencing of the library was performed on Genome Analyzer IIx using a single lane per subject (at a read length of 99 bp and 74 bp for NG 49-1 and NG 50-1, respectively) (Supplementary Table 2). The Illumina pipeline version 1.5 was used for image analysis and base calling.

Exome data analysis. Analysis of the sequencing data was performed according to the previously described data analysis pipeline we have developed^{11,27} by mapping the reads to the human genome (NCBI36/hg18) by Maq and BWA software^{28,29}. Coverage rates and distributions, as well as error positions and frequencies, were detected using perl scripts developed in house. Variants were called using SAMtools³⁰ and annotated for newness as compared to the dbSNP, Personal Genome and 1000 Genomes databases, as well as additional exome sequencing experiments we have performed. New variants were further evaluated for their impact on the encoded protein, conservation across 44 vertebrate species and *Caenorhabditis elegans* and *Drosophila melanogaster*, expression patterns and potential overlap with known miRNAs.

Sanger sequencing. Coding regions and exon-intron boundaries of *LAMC3* were evaluated by Sanger sequencing using standard protocols. Amplicons were cycle sequenced on ABI 9800 Fast Thermocyclers, and post cycle sequencing clean up was carried out with CleanSEQ System (Beckman Coulter Genomics). The amplicons were analyzed on 3730xL DNA Analyzer (Applied Biosystems Inc.).

Animals. All protocols performed in animal experiments were approved by the Institutional Animal Care and Use Committee at Yale School of Medicine. Embryonic day 0.5 was determined as the midday of the day of vaginal plug discovery. For embryonic stages, pregnant females were anesthetized, pups at appropriate stages were extracted from the uterus and the brains were dissected and fixed overnight by immersion in 4% paraformaldehyde in phosphate-buffered saline. Mouse brains were then cryoprotected in 30% sucrose in 4% paraformaldehyde and sectioned in the coronal plane on a Leica sledge cryomicrotome at 40 μ m (Leica Microsystems). Sections were mounted on slides and processed with *in situ* hybridization.

In situ hybridization. Sections were processed for non-radioactive *in situ* hybridization as described previously with minor modifications^{31,32}.

Immunofluorescence. Upon dissection, fetal human brains were immersed whole in 4% paraformaldehyde for 36 h, cryoprotected and frozen, and cryosectioned at 60 μ m. Standard techniques were used after primary antibodies were diluted in blocking solution containing normal donkey serum as follows: rabbit anti-LAMC3 (R96, W. Brunken, SUNY Downstate), 1:5,000; goat anti-SOX2 (Santa Cruz), 1:250; mouse anti-NeuN (Millipore), 1:1,000; mouse anti-SMI-312 (Covance), 1:250; mouse anti-MAP2 (Sigma), 1:1,000; and mouse anti-SRGA1 (Abcam), 1:250.

LAMC3 expression. The data were from a unique, high-quality microarray dataset that measured gene expression within different brain regions throughout human life using the Affymetrix Human Exon 1.0 ST arrays¹⁵ (see URLs).

The log₂-transformed expression values were calculated. The heat map was plotted by averaging the expression of *LAMC3* (*Laminin γ 3*) in the samples from the same cortical area and stage (Fig. 4a). The following cortical areas were sampled: orbital prefrontal cortex (OFC), dorsolateral prefrontal cortex (DFC), ventrolateral prefrontal cortex (VFC), medial prefrontal cortex (MFC), primary motor (M1) cortex (MIC), primary somatosensory (S1) cortex (S1C), posterior inferior parietal cortex (IPC), primary auditory (A1) cortex (A1C), posterior superior temporal cortex (STC), inferior temporal cortex (ITC) and primary visual (V1) cortex (V1C) (Fig. 4a).

To compare the relationship of *LAMC3* expression levels and developmental trajectories, functional gene lists for dendrite development (*MAP1A*, *MAPT* and *CAMK2A*) (Fig. 4e) and synaptogenesis (*SYP*, *SYPL1*, *SYPL2* and *SYN1*) (Supplementary Fig. 8) were manually curated. To summarize the principle gene expression profile of each category, principal component analysis was performed. The first principle component (PC1), which accounts for the majority of variability in the data, was plotted against age (to represent the developmental trajectory) and *LAMC3* expression level. The two independent datasets of synaptic density and the number of basal dendrites in the corresponding brain regions or areas were scaled by $\frac{x-\mu}{\sigma}$, in which μ and σ are the mean and the standard deviation of the values, respectively, corresponding to the time periods for which both our gene expression and the independently generated data were available. The scaled values were plotted against logarithmic age in days, and a cubic spline curve was fitted to display the developmental trajectories. The predicted values on this curve were calculated corresponding to available time points of previously generated independent data on dendrite development^{16,17} and synaptogenesis¹⁸. To identify developmentally co-expressed genes, we calculated the correlation of the temporal expression pattern of all other genes to that of *LAMC3*. The top 50 genes were selected for functional annotation, using DAVID Bioinformatics Resources 6.7 (see URLs)³³.

Primary human neuronal cell culture. All experiments were conducted in accordance with a protocol approved by the Yale Human Investigation Committee (principal investigator, N. Šestan, Protocol# 0605001466). Ventricular zone tissue was dissected from fetal human frontoparietal neocortical wall at 19 weeks of gestation, enzymatically dissociated and cultured in serum-free media in the presence of FGF-2 (20 ng/ml) and epidermal growth factor (20 ng/ml). After 4 weeks in culture, neural progenitor cells were transfected with a construct that co-expresses GFP and hemagglutinin (HA)-tagged human *LAMC3* (BC156274) using nucleofection (Lonza, kit VPG-1004; program A-033). One day after transfection, growth factors were withdrawn to facilitate neuronal differentiation. After 7 days in culture in the absence of growth factors, differentiated neurons were fixed and stained for GFP and HA.

MR data acquisition. MRI scanning was performed on a 3 Tesla scanner (Magnetom Trio, Siemens AG) with a twelve-channel phase-array head coil. A high-resolution T1-weighted three-dimensional anatomical-volume scan was acquired for each participant in the same session before the functional and DTI scans. BOLD signals in the functional scans were measured with an echo-planar imaging sequence. DTI data were acquired using a single-shot spin-echo echo-planar imaging sequence with parallel imaging technique GRAPPA.

MRI structural analysis procedures. Structural analysis involved three-dimensional reconstruction of the participants' cortices and computing cortical thickness using the Freesurfer analysis package (see URLs). After correction, the cortical thickness was calculated at each point as the shortest distance between the white matter-gray matter boundary and the gray matter-cerebrospinal fluid boundary. Finally, the cortical thickness measurement results were mapped on the three-dimensional model of the cortex using a color coding scheme for visualization.

Retinotopic mapping procedures. Experimental software for the retinotopic mapping fMRI scan was written by H.B. and K.D. in the Java programming platform (see URLs). In the scanner, the stimuli were back projected by a video projector fitted with a long throw lens onto a translucent back projection screen placed inside the scanner bore with the help of an angled first surface mirror. The functional scans were performed for retinotopic mapping following the methods developed by two previous studies^{34,12}.

Functional images were preprocessed by using the BrainVoyager QX software (Brain Innovation BI) and the three-dimensional model of the cortices were constructed and inflated for visualization. Functional images from all scans were spatially transformed and aligned with the anatomical volume obtained in the retinotopic mapping scan individually. Boundaries between retinotopic areas were drawn manually with a standard graphics program (Inkscape) after visual inspection of the cross-correlation maps of the BOLD response and the rotating wedges and of the BOLD response and the expanding annuli^{12,34}. The analysis of the second scan of NG 367-1 involved the same steps, except that instead of a cross-correlation analysis, we performed a general linear model analysis to identify the voxels that respond to vertical or horizontal wedges. We then visualized these voxels on the inflated cortex and used this as auxiliary information for manually drawing the boundaries between early visual areas.

DTI analysis procedures. White matter pathways were identified using the MRI Atlas of Human White Matter³⁵ and fiber tracking was performed in MedINRIA software package (see URLs). Fractional Anisotropy and Mean Diffusivity maps were computed in DTI studio³⁶ in three manually defined region of interest. Initial measurements are reported, and no further statistical analysis was performed.

27. Choi, M. *et al.* Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. *Proc. Natl. Acad. Sci. USA* **106**, 19096–19101 (2009).
28. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **25**, 1754–1760 (2009).
29. Li, H., Ruan, J. & Durbin, R. Mapping short DNA sequencing reads and calling variants using mapping quality scores. *Genome Res.* **18**, 1851–1858 (2008).
30. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009).
31. Louvi, A., Sisodia, S.S. & Grove, E.A. Presenilin 1 in migration and morphogenesis in the central nervous system. *Development* **131**, 3093–3105 (2004).
32. Stillman, A.A. *et al.* Developmentally regulated and evolutionarily conserved expression of SLITRK1 in brain circuits implicated in Tourette syndrome. *J. Comp. Neurol.* **513**, 21–37 (2009).
33. Dennis, G. Jr. *et al.* DAVID: Database for Annotation, Visualization, and Integrated Discovery. *Genome Biol.* **4**, P3 (2003).
34. Engel, S.A., Glover, G.H. & Wandell, B.A. Retinotopic organization in human visual cortex and the spatial precision of functional MRI. *Cereb. Cortex* **7**, 181–192 (1997).
35. Song, S.K. *et al.* Demyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. *Neuroimage* **17**, 1429–1436 (2002).
36. Jiang, H., van Zijl, P.C., Kim, J., Pearlson, G.D. & Mori, S. DtiStudio: resource program for diffusion tensor computation and fiber bundle tracking. *Comput. Methods Programs Biomed.* **81**, 106–116 (2006).